Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.81 |
| ▸ | TUBB | P07437 | 3/20 | 0.81 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.81 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.81 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.81 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.81 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.81 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.81 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.81 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.81 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.81 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.81 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.81 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.81 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | ATM | Q13315 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 14/20 | 0.75 |
| ▸ | NPC1 | O15118 | 13/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508832 | 0.90 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1508835 | 0.90 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17890027 | 0.86 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17890029 | 0.86 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12692529 | 0.86 | RAB9A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16448290 | 0.82 | TUBB4A (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17890024 | 0.82 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16448291 | 0.82 | TUBB4A (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17890026 | 0.82 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17890111 | 0.81 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-10808247-B2 | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach | PHIO PHARMACEUTICALS CORP. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2020-06-04 | — | — | US | disclosed |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-20180195066-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH | RXI PHARMACEUTICALS CORPORATION (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180195066-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH | RXI PHARMACEUTICALS CORPORATION (US) | 2018-07-12 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095596-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011047129-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RESEARCH INSTITUTE (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195066-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH | SOD1, POLRMT, SMN1; SMN2 | TUBB4A 1226/4885TUBB 648/4885TUBA3C 1553/4885 |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | TUBB4A 572/4885TUBB 621/4885TUBA3C 2556/4885 |
| US-10808247-B2 | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach | SOD1, POLRMT, SMN1; SMN2 | TUBB4A 1226/4885TUBB 648/4885TUBA3C 1553/4885 |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | TUBB4A 520/4885TUBB 594/4885TUBA3C 2363/4885 |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | TUBB4A 520/4885TUBB 594/4885TUBA3C 2363/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | TUBB4A 520/4885TUBB 594/4885TUBA3C 2363/4885 |
| US-20120245166-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | TUBB4A 520/4885TUBB 594/4885TUBA3C 2363/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | TUBB4A 520/4885TUBB 594/4885TUBA3C 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.